Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.
- DOI
- 10.1002/cam4.71981
- Published
- 2026 May
- Container
- Cancer medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cam4.71981,
title = {Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.},
author = {Maeda O and Tanaka C and Furukawa K and Miyata K and Shimizu D and Sugita S and Nakanishi K and Hirose T and Mizuno K and Kinoshita F and Kuwatsuka Y and Ando M and Kanda M and Kawashima H and Ando Y},
year = {2026},
journal = {Cancer medicine},
doi = {10.1002/cam4.71981},
url = {https://doi.org/10.1002/cam4.71981}
}RIS
TY - JOUR TI - Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol. AU - Maeda O AU - Tanaka C AU - Furukawa K AU - Miyata K AU - Shimizu D AU - Sugita S AU - Nakanishi K AU - Hirose T AU - Mizuno K AU - Kinoshita F AU - Kuwatsuka Y AU - Ando M AU - Kanda M AU - Kawashima H AU - Ando Y PY - 2026 JO - Cancer medicine DO - 10.1002/cam4.71981 UR - https://doi.org/10.1002/cam4.71981 ER -
APA
O, M., C, T., K, F., K, M., D, S., S, S., K, N., T, H., K, M., F, K., Y, K., M, A., M, K., H, K., & Y, A. (2026). Feasibility Study of Trifluridine/Tipiracil and Zolbetuximab as Third- or Later-Line Chemotherapy for CLDN18.2-Positive and HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Study Protocol.. Cancer medicine. https://doi.org/10.1002/cam4.71981
Source records
- pubmed · retrieved 2026-09-26T23:29:39.481Z
- europe-pmc · retrieved 2026-09-26T23:29:39.498Z
- doaj · retrieved 2026-09-26T23:29:39.501Z